Stopped: Study never started
The purpose of this study is to develop an innovative, safe, acceptable, feasible, and efficacious integrated CLASP-PE intervention and to Collect pilot data to evaluate the preliminary evidence of the promise of the intervention. We hypothesize that the CLASP-PE intervention will demonstrate safety, acceptability, feasibility, and efficacy in the open trial.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with a diagnosis of post-traumatic stress syndrome(PTSD)as assessed by The Clinician Administered PTSD Scale for DSM 5 (CAPS 5)
Timeframe: Baseline
Number of participants with a diagnosis of post-traumatic stress syndrome(PTSD)as assessed by The Clinician Administered PTSD Scale for DSM 5 (CAPS 5)
Timeframe: end of treatment (Upto 16 weeks from start of treatment)
Number of participants with a diagnosis of post-traumatic stress syndrome(PTSD)as assessed by The Clinician Administered PTSD Scale for DSM 5 (CAPS 5)
Timeframe: 3 months post treatment
Number of participants with a diagnosis of post-traumatic stress syndrome(PTSD)as assessed by The Clinician Administered PTSD Scale for DSM 5 (CAPS 5)
Timeframe: 6 months post treatment
The extent to which participants have been bothered by PTSD symptoms as assessed by the PTSD Checklist for DSM-5 (PCL-5) assessment.
Timeframe: Baseline
The extent to which participants have been bothered by PTSD symptoms as assessed by the PTSD Checklist for DSM-5 (PCL-5) assessment.
Timeframe: before each session(participants will complete 8-16 weekly or twice weekly individual therapy sessions)
The extent to which participants have been bothered by PTSD symptoms as assessed by the PTSD Checklist for DSM-5 (PCL-5) assessment.
Timeframe: end of treatment (Upto 16 weeks from start of treatment)
The extent to which participants have been bothered by PTSD symptoms as assessed by the PTSD Checklist for DSM-5 (PCL-5) assessment.
Timeframe: 3 months post treatment
The extent to which participants have been bothered by PTSD symptoms as assessed by the PTSD Checklist for DSM-5 (PCL-5) assessment.
Timeframe: 6 months post treatment
Number of patients with characteristic attitudes and symptoms of depression as measured by the Black depression Inventory (BDI)
Timeframe: Baseline
Number of patients with characteristic attitudes and symptoms of depression as measured by the Black depression Inventory (BDI)
Timeframe: before each session(participants will complete 8-16 weekly or twice weekly individual therapy sessions)
Number of patients with characteristic attitudes and symptoms of depression as measured by the Black depression Inventory (BDI)
Timeframe: end of treatment(Upto 16 weeks from start of treatment)
Number of patients with characteristic attitudes and symptoms of depression as measured by the Black depression Inventory (BDI)
Timeframe: 3 months post treatment
Number of patients with characteristic attitudes and symptoms of depression as measured by the Black depression Inventory (BDI)
Timeframe: 6 months post treatment
Severity of depression as assessed by the Quick Inventory of Depression Symptomatology (QIDS) The QIDS is a 16-item measure that is scored on a 4 point scale from 0-3 with a higher number indicating more severity of depression.
Timeframe: Baseline
Severity of depression as assessed by the Quick Inventory of Depression Symptomatology (QIDS) The QIDS is a 16-item measure that is scored on a 4 point scale from 0-3 with a higher number indicating more severity of depression.
Timeframe: before every session(participants will complete 8-16 weekly or twice weekly individual therapy sessions)
Severity of depression as assessed by the Quick Inventory of Depression Symptomatology (QIDS) The QIDS is a 16-item measure that is scored on a 4 point scale from 0-3 with a higher number indicating more severity of depression.
Timeframe: end of treatment (Upto 16 weeks from start of treatment)
Severity of depression as assessed by the Quick Inventory of Depression Symptomatology (QIDS) The QIDS is a 16-item measure that is scored on a 4 point scale from 0-3 with a higher number indicating more severity of depression.
Timeframe: 3 months post treatment
Severity of depression as assessed by the Quick Inventory of Depression Symptomatology (QIDS) The QIDS is a 16-item measure that is scored on a 4 point scale from 0-3 with a higher number indicating more severity of depression.
Timeframe: 6 months post treatment
Intensity of attitudes, behaviors and plans to commit suicide over the prior week as assessed by the Beck Scale for Suicidal ideation(BSSI)
Timeframe: Baseline
Intensity of attitudes, behaviors and plans to commit suicide over the prior week as assessed by the Beck Scale for Suicidal ideation(BSSI)
Timeframe: end of treatment (Upto 16 weeks from start of treatment)
Intensity of attitudes, behaviors and plans to commit suicide over the prior week as assessed by the Beck Scale for Suicidal ideation(BSSI)
Timeframe: 3 months post treatment
Intensity of attitudes, behaviors and plans to commit suicide over the prior week as assessed by the Beck Scale for Suicidal ideation(BSSI)
Timeframe: 6 months post treatment
Measure of suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: Baseline
Measure of suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: end of treatment (Upto 16 weeks from start of treatment)
Measure of suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: 3 months post-treatment
Measure of suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Timeframe: 6 months post-treatment
Number of patients with anxiety, mood, psychotic, substance, and eating disorders as assessed by the MINI International Neuropsychiatric Interview (MINI)
Timeframe: Baseline
Extent to which client was satisfied with the training as assessed by the Client Satisfaction Questionnaire (CSQ)
Timeframe: end of treatment (Upto 16 weeks from start of treatment)
Feedback form participants as assessed by the Qualitative interview(QI) which will include a series of open ended questions aimed at eliciting feedback from participants about their perspective on the PE-CLASP Intervention
Timeframe: end of treatment (Upto 16 weeks from start of treatment)